Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.
- 07 Aug 2018 Results (n=80) published in the Investigational New Drugs.
- 21 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.